News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Investor's Business Daily9d agoneutral
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A DecadeBusiness Wire9d agoneutral
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor ConferencesMT Newswires9d agobullish
UBS Adjusts Gilead Sciences Price Target to $195 From $175, Maintains Buy RatingInsider Monkey41d agoneutral
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?Insider Monkey41d agoneutral
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?Insider Monkey41d agoneutral
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?Simply Wall St.41d agoneutral
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?Insider Monkey42d agoneutral
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?Insider Monkey42d agoneutral
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?Insider Monkey42d agoneutral
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?Insider Monkey42d agoneutral
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?MarketBeat48d agoneutral
Lakefront Biotherapeutics Targets 2027 Registrational Trials for GamgertamigSimply Wall St.50d agoneutral
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?Insider Monkey51d agoneutral
Gilead Strengthens HIV Growth Platform with Expanded Latin America AccessInvestorsHub53d agoneutral
Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation